LRF Publishes Proceedings of the Inaugural International Marginal Zone Lymphoma Scientific Workshop

The Lymphoma Research Foundation (LRF) recently published a white paper summarizing the proceedings from the inaugural International Scientific Workshop on Marginal Zone Lymphoma held in April 2019.

Marginal zone lymphoma (MZL) is an uncommon non-Hodgkin lymphoma with a typically indolent clinical course. The management of MZL is complicated by an incomplete understanding of the molecular etiology and natural history of the multiple presentations of MZL. Despite recent efforts to develop targeted chemotherapies and immunotherapies in lymphoma, MZL has long been a neglected area of lymphoma research, particularly in the United States.

At this two-day scientific workshop, MZL experts from North America and Europe discussed the current state of MZL treatment and research and highlighted new lines of inquiry intended to move the MZL field forward, in terms of both understanding the core biology of the disease and treating the disease most effectively. At the conclusion of the workshop, a discussion session took place that focused on currently unmet needs in the field of MZL, with an emphasis on identifying opportunities for large-scale study designs that leverage the opportunities for collaboration that can be facilitated by LRF.

Proceedings of the 2019 Lymphoma Research Foundation Marginal Zone Lymphoma Scientific Workshop provides a summary of the workshop proceedings, presenting the key findings of each speaker, on topics including:

  • The biology and pathology of MZL;
  • The epidemiology and natural history of MZL;
  • MZL transformation;
  • MZL assessment and response criteria;
  • MZL treatment; and
  • MZL clinical trials

The white paper also highlights the unmet needs identified during the post-workshop discussion with suggested immediate and long-term solutions.

Lymphoma Consortia, Initiatives and Scientific Workshops

LRF seeks to eradicate this disease by supporting innovative research and the development of new and improved treatments for lymphoma. Direct investment in cutting-edge science is the primary way LRF advances its mission. Facilitating collaboration and partnerships among academic scientists, clinicians, government, and regulatory agencies, and patients is also a critical component of this work.

Through its global lymphoma consortia, research initiatives, and scientific workshops, LRF mobilizes the research community to overcome systemic challenges and speed the progress new treatments are developed.  Learn More >